Genus Capital Management Inc. Makes New $2.16 Million Investment in United Therapeutics Corporation $UTHR

Genus Capital Management Inc. acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,440 shares of the biotechnology company’s stock, valued at approximately $2,163,000.

Several other hedge funds have also modified their holdings of UTHR. Torren Management LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $26,000. Activest Wealth Management raised its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC raised its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. raised its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new stake in United Therapeutics in the fourth quarter worth $31,000. 94.08% of the stock is owned by institutional investors.

Insider Activity at United Therapeutics

In other news, Director Nilda Mesa sold 258 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $581.93, for a total value of $150,137.94. Following the completion of the sale, the director directly owned 5,028 shares in the company, valued at approximately $2,925,944.04. The trade was a 4.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $562.82, for a total transaction of $4,671,406.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $25,423,705.04. The trade was a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 555,473 shares of company stock valued at $310,786,074. Company insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on UTHR. HC Wainwright raised their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Bank of America lifted their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Price Performance

Shares of UTHR stock opened at $568.43 on Monday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The firm has a 50-day moving average of $563.25 and a 200-day moving average of $512.08. The company has a market cap of $24.13 billion, a P/E ratio of 20.98, a P/E/G ratio of 1.84 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the business posted $6.63 EPS. As a group, research analysts expect that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.